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our sample, a total of 176,891 patients hadAF. By reference to the totalmembership
of the twomedical insurance funds, the prevalence of AFwas 2.132% (men: 2.369%;
women: 1.895%). The average age of these AF patients was 73.1 years, and 55.5%
(98,190 patients) were male. The incidence of AF in our sample was 4358 cases per
1000 person-years in men and 3.868 cases in 1000 person-years in women. AF
prevalence/incidence clearly depends on age and gender. CONCLUSIONS: A com-
parison of the distribution of AF prevalence/incidence in our population with that
in already published studies shows that our figures are higher, especially in the age
groups above 70 years. Obviously, AF prevalence/incidence are further increasing
in industrialized countries.
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OBJECTIVES: In this study we performed congestive heart failure (CHF) gap analy-
sis for the residents of Lake county, IL based on the hospital discharge data col-
lected between 2001- 2009.METHODS: The hospital discharge data between 2001-
2009 for primary diagnosis of CHFwas analyzed. All patients ( 4 yr to 85yr) were
categorized in 10 age groups and comparative analysis was performed. Patient
cases for systolic and diastolic CHF were identified using ICD-9 codes for systolic
and diastolic heart failures.RESULTS:N 827,355 discharge recordswere screened.
Overall therewereN15299 cases thatwere dischargedwith the primary diagnosis
of systolic CHF reflecting a crude rate of 1.8 %. The reported rate by the AHQR for
state of IL in 2006 was 501.9/ 2.2 cases. There were N7851 female and N7448
male cases. Age adjusted rate per 100,000 patientswas 956.06/ 0.09 cases. There
were N1350 cases of diastolic heart failure i.e. an age adjusted rate of 71.48 /
2.24 cases (crude rate of 163.17 per 100,000). Most often length of stays ranged from
2 to 5 days. Analysis of residential zip codes indicates one suburb with a high
percentage of Hispanics and blacks with the highest reported cases (Waukegan
1557 cases). The overall age adjusted systolic CHF rate in Waukegan was
1313.35/ 36.47 cases per 100,000 which is significantly greater than the average
calculated rate for residents of Lake County [OR1.38 (1.30-1.47), P0.0001]
CONCLUSIONS: Lake County data suggest a higher rate of age-adjusted discharge
rate for CHF in parts of Lake county, IL, USA with a high % of Hispanic and black
population.
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PREVALENCE OF HYPERTENSION IN AMASSOMA, SOUTHERN IJAW, BAYELSA
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OBJECTIVES: Hypertension is a public health problem worldwide, but the preva-
lence in Amassoma, which hosts the Niger Delta University, is not known. The
objective of the study was to investigate the prevalence of hypertension in the
locality and the extent of control in diagnosed cases. METHODS: Four hundred
adults selected through stratified sampling across the various compounds called
“AMA” and aged 20 years and above were included. It took place in between Feb-
ruary and May 2011.It involves interviewer administered questionnaires on demo-
graphics, predisposing factors and relevant medication history and measurement
of respondents’ blood pressure (BP) (on two separate occasions), weight and height.
The Body Mass Index (BMI) calculated and the data were appropriately analysed.
RESULTS:Majority of respondentswere female. Almost half of respondents (46.5%)
had their BMI above normal, 15.3% (61) of which falls within the obese region
(30.0kg/m2). Crude prevalence rate of hypertension ( BP of 140/90 mmHg)in the
community was 15.0% (60) out of which 13.8 % (55) were previously diagnosed. The
hypertension was that of Stage I (140-159/90-99mmHg) in 11.5% (46) and Stage II
(160/100 mmHg) in 3.5% (14). About half (51.0%) of previously diagnosed cases
(n55) were on any form of drug or the other. Another 23.5% had their BP in
pre-hypertensive stage (120-139/80-89mmHg). The prevalence rate among 40 years
and above was 10.5%. There was no statistically significant difference between
both sexes (2; p0.241), with 12.5% (n240) in females and 18.7% (n140) in male
respondents. The variation of BP among the various age groups was not significant
(p0.399; ANOVA). CONCLUSIONS: The prevalence of hypertension in Amassoma
community of Southern Ijaw, Bayelsa State is 15.0% with a pre-hypertension in
another 23.5% of the community. There is poor control of BP among previously
diagnosed hypertensive patients.
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OBJECTIVES: In this study we performed hypertension gap analysis for the resi-
dents of Lake county, IL based on the hospital discharge data collected between
2001- 2009.METHODS: The hospital discharge data between 2001-2009 for primary
diagnosis of HTN was analyzed. All patients ( 4 yr. to 85yr ) were categorized in
10 age groups and comparative analysis were performed. Cases for essential hy-
pertension were identified using ICD-9 codes . RESULTS: N 827,355 discharge
records were screened. Overall there were N1959 cases ( malignant 393; be-
nign17 and non-specific  1549 ) with the primary diagnosis of hypertension
reflecting a crude rate of 0.236%. consistent with a previous report by the state of IL
in 2004. There were N1249 female and N710 male cases, The age-adjusted rate
per 100,000 patients was 196.85 / 7.37 for females (crude rate of 248.77) and
236.41 / 10.92 cases in men ( crude rate of 218.27). For majority of patients the
length of stay were either 1 day (n744), 2 days (n567) or 3 days (n318) which is
comparable to IL data - an average of 2.6 days. Analysis of data based on residential
zip codes indicates 3 suburbs with a high percentage of Hispanics and blacks with
the highest reported cases( Waukegan 243 cases, Zion 102 cases, North Chi-
cago99 cases).Waukegan has greater than 50%hispanics ( 70%Mexican heritage).
The overall age-adjusted HTN rate in Waukegan was 279.2 / 19.11 cases per
100,000 which is significantly greater than the average calculated rate for either
males or females in the lake county [OR females1.42 (.64-.81), P.0001; OR-
males1.18 (.73-.98), P0.022] CONCLUSIONS: This data suggest a significantly
higher rate of age adjusted discharge rate for HTN in parts of Lake county, IL, USA
that have a high % of Hispanic and black population.
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OBJECTIVES: About 16,000 children suffer a cardiac arrest (CA) in the US each year.
Children having CA in an inpatient setting experience a lower death rate than
children having CA outside the hospital. The objectives of this study were to: 1.)
describe the inpatient CA pediatric population; 2.) determine the primary cause of
hospital admission for these patients; and 3.) determine whether the type of hos-
pital in which the patient was treated impacted survival post CA.METHODS: Dis-
charges for children aged 0-20 were selected from the Kids’ Inpatient Database
(KID) for the years 2003,2006,and 2009 if a primary or secondary diagnosis was
identified as ICD-9 code 427.5 (CA). Frequencies of discharges with CA were calcu-
lated and stratified by various patient and hospital characteristics, includingMajor
Diagnostic Code (MDC) to determine the primary cause for the hospital admission
and hospital type. Hospital type was classified by the National Association of Chil-
dren’s Hospitals and Related Institutions (NACHRI) to be a children’s hospital, a
children’s unit in a general hospital, or a non-children’s hospital. RESULTS: The
rate of death in pediatric hospitalizations declined from 66.46% in 2003 to 52.73% in
2009. The most common admission diagnoses involved the circulatory system
(about 27% each year), injuries from poison and toxic effects of drugs (about 10%
each year), and the respiratory system (16%, 18%, and 19%, for 2003, 2006, and 2009
respectively). Although the overall death rate decreased from 2003-2009, the rate of
decline was greater for both children’s hospitals and children’s units in general
hospitals. Whereas the rate declined from 66% to 57% for non-children’s hospitals
from 2003-2009, the rate declined from 64% to 51% for children’s hospitals.
CONCLUSIONS: The pediatric death rate is high in an inpatient setting. Between
the years 2003-2009, however,the death rate has declined, especially in pediatric
hospitals.
PCV28
USING RISK-ADJUSTED EXPECTED EVENT RATE TO EVALUATE INDIVIDUAL
HOSPITAL QUALITY PERFORMANCE IN PERCUTANEOUS CORONARY
INTERVENTIONS (PCI)
Wang Y1, Melilli L1, Magee G2, Baumer D3
1The Medicines Company, Parsippany, NJ, USA, 2Premier, Charlotte, NC, USA, 3Premier
Healthcare Alliance, Charlotte, NC, USA
OBJECTIVES: Recent US healthcare legislation highlights the need to assess insti-
tutional performance relative to regional or national norms. The study described
here introduces a simple and effective methodology for risk adjusted outcome
rates at the hospital level using observational data. It evaluates 4 regional hospitals
performance for inpatient PCI compared to all Premier hospitals. METHODS: A
total of 617,332 PCI patients from 324 hospitals between 2004 and 2009 were iden-
tified in the Premier Hospital Database. Clinical outcomeswere Clinically Apparent
Bleeding (CAB), defined by ICD-9 codes, and Inpatient Mortality (IM). Logistic mod-
els for each clinical outcome adjusted patient demographics, baseline comorbidity,
disease status, and hospital variables. Estimated patient level probabilities were
summed as the expected events for each hospital. Observed events divided by the
expected events produced anObserved to Expected Ratio (OER). OER 1 implies the
risk adjusted hospital event rate is higher than expected. RESULTS: The number of
PCI patients for hospitals 1through 4 were 1,737, 966, 990, and 309 respectively.
Observed CAB rates (%) were 4.4, 8.0, 3.8, and 8.7, compared to an overall rate of
5.4% for all Premier hospitals. The CAB OERs were 1.09, 1.75, 0.98, and 1.04. Unad-
justed IM rates (%) for hospitals 1 through 4 were 1.2, 1.6, 0.3, and 1.6. IM OERs were
0.86, 0.95, 0.40, and 1.02. Overall Premier IMwas 1.3%. Observed CAB for hospitals 2
and 4 were at least 48% higher than overall Premier. Post, however, risk adjust-
ment, hospital 2 remainedhighwhile hospital 4 decreased to 1.04, similar to overall
Premier. In contrast, the mortality OER for hospital 2 fell below the Premier bench-
mark despite its high observed rate. CONCLUSIONS: The OER provides a simple,
methodologically sound approach to review outcomes. It allows subpopulations to
have adjusted outcomes that can be compared to appropriate peer groups.
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OBJECTIVES:To examine the association ofmissed diagnoseswith patient, ED, and
hospital characteristics using administrative dataMETHODS:We conducted a ret-
rospective analysis ofmissed stroke diagnosis using linked inpatient discharge and
ED visit records from the 2009 HCUP State Inpatient Databases (SID) and 2008 and
2009 HCUP State Emergency Department Databases (SEDD). This study was set in
inpatient facilities and emergency departments in nine states (CA, FL, HI, MA, MO,
NE, NY, SC, TN). We identified patients who were admitted for stroke and had a
“treat and release” ED visit in the prior 30 days for a benign headache or dizziness.
We excluded stroke admissions for patients under 18 years and for certain other
admissions (not occurring through the ED; occurring in facilities with fewer than
seven total stroke admissions during 2009; and with missing covariate values).
RESULTS: Males (OR0.75; p 0.001) and older individuals (compared to 18-44,
45-64: OR0.43; 65-74: OR0.28; 75: OR0.19; p.001) had lower odds, while
Blacks (OR1.17; p.03), Asian/Pacific Islanders (OR1.29; p0.03), and Hispanics
(OR1.30; p0.001) had higher odds of a missed stroke diagnosis. Medicare
(OR0.66; p .001) and Medicaid (OR0.70; p 0.001) patients had lower odds of a
missed diagnosis compared to privately-insured patients. Non-teaching hospitals
(OR1.45; p0.002) and hospitals with low volume (OR1.57; p0.008) had higher
odds of a missed diagnosis. CONCLUSIONS: Physicians in the ED who are evaluat-
ing patients with headache and dizziness might want to be more attuned to the
possibility of stroke in women, younger patients, and nonwhite patients.
CARDIOVASCULAR DISORDERS – Cost Studies
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OBJECTIVES: Hyperlipidemic patients at risk of cardiovascular (CV) events who
receive simvastatin or atorvastatin as a first-line treatment may be less likely to
meet low-density lipoprotein cholesterol (LDL-C) goals and thus more likely to
experience CV events than patients who initiate on rosuvastatin. A deterministic
model was developed to estimate the budget impact over 3 years of initiating
high-risk patients in a hypothetical managed health care (MHC) plan on rosuvas-
tatin rather than simvastatin or atorvastatin. METHODS: Among 1,000,000 health
plan members aged 18 years, 1,000 patients (0.1%) were assumed to initiate
statins. The average baseline LDL-C level was 160mg/dL. Two scenarios weremod-
eled: in scenario 1 all patients were initiated on simvastatin or atorvastatin and
titrated to a higher dose, or switched to atorvastatin (if initiated on simvastatin) or
rosuvastatin; in scenario 2, 50% of the 530 high-risk patients – based on National
Cholesterol Education Program (NCEP) guidelines – were initiated on rosuvastatin.
Product labeling, clinical trial results, national prescription claims data, and pub-
lished literature were used to populate the model. Drug acquisition, administra-
tion, and event costs were considered. RESULTS: Over 3 years, 61 additional pa-
tients reached their LDL-C goal in scenario 2, comparedwith scenario 1 (770 vs. 709,
respectively), at an increased cost of $637,000 ($1,714,000 vs. $1,077,000, respec-
tively). The additional permember permonth (PMPM) cost of scenario 2 to theMHC
plan was $0.02. When the cost of managing CV events was accounted for, the
budget impact decreased to $634,000. CONCLUSIONS: Although the model has
some limitations, it highlights the value of appropriate prescribing of statins. Ini-
tiating high-risk hyperlipidemic patients on rosuvastatinmay increase the number
of patients reaching LDL-C goals (defined in NCEP guidelines) at a relativelymodest
increase in PMPM cost to a MHC plan, despite the low cost of generic statins.
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OBJECTIVES: Ticagrelor (TG) is a new oral platelet inhibitor with improved thera-
peutic effect and safety profile than clopidogrel. Yet it is not listed in the public
hospital formulary of Hong Kong, hence suitable patients do not have general
access to it. A budget impact analysis would thus help provide evidence to assist
local budget holders in decision making processes. METHODS: A budget impact
model was built to allow assessment of the budgetary impact to the local health
care system from a government perspective if TG is introduced into the local mar-
ket. The scenarios adopted were world with andwithout TG. A hypothetical cohort
of 16,000 patients with acute coronary syndrome (ACS) was used as the population.
Proportion of ACS events was estimated using HK-specific values. Sources of drug
and DRGs costs were from the local public hospital authority as released in 2011.
Market shares of TG as compared to clopidogrel (branded) for world without and
with TG over a 5-year period were assumed to be 0% and 10-25% (with 5% incre-
ment/year) respectively. RESULTS: Over a 5-year period, the budget impact of
using TG was estimated to range from 1.18% (year-1) to 3.21% (year-5) if TG was
introduced. The actual extra cost per patient was estimated to range from
HKD423 (USD54, 1USD7.8HKD) in year-1 to HKD1,135 (USD146) in year-5. De-
terministic sensitivity analysis performed suggested that proportions of bleed-
ing between the 2 drugs and drug cost are the most influential variables. The
drug acqusition costs were partially offset by improved therapetic outcomes,
reduction in side effects and shortened hospital stay. CONCLUSIONS: Results of
the present budget impact analysis suggest that introducing TG into the market
of Hong Kong would only have minimal effect on the health care budget. Budget
holders should consider TG as an option to clopidogrel in view of its better
therapeutic effects and safety profile.
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OBJECTIVES:Todescribe and compare health resource utilization and related costs
of patients with chronic thromboembolic pulmonary hypertension (CTEPH) and
pulmonary arterial hypertension (PAH) in six European countries. METHODS: We
reviewed medical charts from patients diagnosed with CTEPH or PAH and treated
with PAH-specific therapy: Endothelin-receptor antagonists (ERA), prostacyclin an-
alogues (PA) or PDE5-inhibitors (PDEi). Data on demographic and clinical charac-
teristics, PAH-medication, and health resource utilization were retrospectively ab-
stracted from patients’ medical records at specialized PH treatment centers across
six European countries. Resource utilizationwas valued using country-specific unit
costs; descriptive statistical analyses were performed. RESULTS: Twenty one hos-
pitals documented 405 patients (120 in CTEPH and 285 in PAH). CTEPH patients
were older with a mean age of 67.5 12.1 years versus 55.3 15.6 years for PAH
patients. In the CTEPH group, 60% were female (PAH 74.4%) and both groups were
on average observed for 25.7months (SD 10.2). At baseline, 59.2% of CTEPH patients
received ERA (PAH 53%), 5.8% PA (PAH 5.0%), and 34.2% PDE5i (PAH 37.0%). CTEPH
patients experienced 1.8 2.2 hospitalizations per year accounting for 15.0 26.0
days in hospital, compared to PAH patients with 1.52.4 hospitalizations and 20.6
44.7 days, respectively. In both groups annual costs of PH medication was the
predominant cost factor averaging €37,346 23,183 in CTEPH and €38,840 29,072
in PAH, followed by hospitalizations (CTEPH €4,554 7,894, PAH €6,254 €13,571)
and concomitant medications (CTEPH €2,534  €2505, PAH €1,301  €1,514). Other
health care resource items only accounted for marginal additional costs in both
groups. CONCLUSIONS: These data show similar overall costs for patients with
PAHandCTEPH. Although, for CTEPHoff-label andwithout evidence from random-
ized trials, in both groups, PAH-specific medication was the predominant cost
factor. CTEPH patients tended to have higher costs for concomitant medication
whereas hospitalizations were more common in PAH.
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OBJECTIVES: Atrial Fibrillation (AF) greatly increases the risk of stroke. AF-related
stroke is associated with higher mortality, worse outcome and higher health care
cost, which is substantial for patients and society. Few studies, however, of the
costs of AF-related stroke were available in China. This study aimed to assess and
compare the hospital costs and length-of-stay in patients with AF and AF-related
stroke in China from payer’s perspective.METHODS:Data were extracted from the
BasicMedical Insurance Databases in 2010. 385 patientswere randomly selected by
stratified two-stage sampling. All information of patient demographic characters,
clinical and costs were collected for the analysis. The descriptive statistics was
used to describe patients’ demographic characters, the hospital stay and the hos-
pital costs. Univariate and multivariable analyses were also used in the data
analysis. RESULTS: Total 385 patients (mean age 70.6 years; 51.4% male) were
evaluated, 59.0% of patients with AF and 41.0% of patients with AF-related stroke.
The mean length-of-stay was 14.2 days (11.9 days AF and 17.5 days AF related
stroke; P 0.001); the mean total cost was 17630.42 (median: 9323.25, IQR: 5086.87-
20193.43): 17734.93 (median: 6891.92, IQR: 3898.78-20751.16) with AF and 17480.27
(median: 11975.32, IQR: 7863.3-19941.85)withAF-related stroke (P0.001). Themul-
tiple linear regressions showed that the hospital cost of AF-related stroke was 81%
higher than the hospital cost of AF. Patientswith basicmedical insurance for urban
employees had 39.6% higher costs than those with basic medical insurance for
urban residents (P0.001). Patients from tertiary hospitals had 97.8% higher costs
than those from primary hospitals; (P0.001) and patients frommunicipalities had
58.0% higher costs than those from prefecture-level cities; (P0.01).
CONCLUSIONS: Patients with AF-related stroke is associated with significantly
higher hospital costs compared with those with AF. It implied that stroke preven-
tion in AF may have potential cost savings.
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OBJECTIVES: The lack of data has presented a challenge to perform pharmacoeco-
nomic research in Asia. However, efforts have been made to make cost data avail-
able and this study presents newly available data from clinical costing databases in
Malaysia, Indonesia and the Philippines. The objective is to determine the length of
stay and treatment cost per episode of acutemyocardial infarction (MI).METHODS:
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